Retrospective studies show that 80% of patients with EGFR mutant non-small cell lung cancer (NSCLC) tumors treated with EGFR TKIs show radiographic and clinical responses with better progression free survival (PFS) and overall survival (OS) compared to wild type [11, 12]. Here, EGFR is linked to non-small cell lung carcinoma.